<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font3" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font4" size="10" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="10" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font6" size="9" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font7" size="7" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font8" size="8" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font9" size="8" family="AkzidenzGroteskBE-It,Italic" color="#ffffff"/>
	<fontspec id="font10" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font11" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font12" size="17" family="LTMUXQ+Helvetica" color="#000000"/>
	<fontspec id="font13" size="17" family="LTMUXQ+Helvetica" color="#000000"/>
<text top="42" left="311" width="245" height="7" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/7/1/R145<b>Available online</b></text>
<text top="735" left="569" width="19" height="8" font="font3" id="p1_t2" reading_order_no="63" segment_no="12" tag_type="text">R149</text>
<text top="389" left="57" width="241" height="9" font="font4" id="p1_t3" reading_order_no="8" segment_no="5" tag_type="text">tive with 66.3 cells, the parental cell line from which A2L2</text>
<text top="401" left="57" width="226" height="9" font="font4" id="p1_t4" reading_order_no="9" segment_no="5" tag_type="text">was derived by transfection with neu (data not shown).</text>
<text top="424" left="57" width="238" height="8" font="font6" id="p1_t5" reading_order_no="10" segment_no="6" tag_type="title">Protection from tumor challenge in a mammary fat pad</text>
<text top="436" left="57" width="231" height="8" font="font6" id="p1_t6" reading_order_no="11" segment_no="6" tag_type="title">prevention model following vaccination with VRP-neu<i>neu </i></text>
<text top="448" left="57" width="240" height="9" font="font4" id="p1_t7" reading_order_no="12" segment_no="7" tag_type="text">Groups of mice ( n = 7 per group) were vaccinated subcu-</text>
<text top="459" left="57" width="240" height="9" font="font4" id="p1_t8" reading_order_no="13" segment_no="7" tag_type="text">taneously with 10 5 IU or 10 6 IU VRP- neu or with 10 6 IU<b>Protection from tumor challenge in a mammary fat pad </b></text>
<text top="471" left="57" width="240" height="9" font="font4" id="p1_t9" reading_order_no="14" segment_no="7" tag_type="text">VRP-HA three times at 14-day intervals. Two weeks after<b>prevention model following vaccination with VRP-neu</b></text>
<text top="483" left="57" width="240" height="9" font="font4" id="p1_t10" reading_order_no="15" segment_no="7" tag_type="text">the final vaccination, the mice were challenged with 2.5 Ã—</text>
<text top="494" left="57" width="241" height="10" font="font4" id="p1_t11" reading_order_no="16" segment_no="7" tag_type="text">10 4 A2L2 cells injected into a mammary fat pad. Five weeks<i>n </i></text>
<text top="506" left="57" width="240" height="9" font="font4" id="p1_t12" reading_order_no="17" segment_no="7" tag_type="text">after tumor challenge, the largest tumor dimension was</text>
<text top="518" left="57" width="240" height="9" font="font4" id="p1_t13" reading_order_no="18" segment_no="7" tag_type="text">measured and the mice were killed. If a tumor was present,</text>
<text top="530" left="57" width="241" height="9" font="font4" id="p1_t14" reading_order_no="19" segment_no="7" tag_type="text">its mass was determined. All of the mice vaccinated with</text>
<text top="542" left="57" width="240" height="9" font="font4" id="p1_t15" reading_order_no="20" segment_no="7" tag_type="text">VRP-HA had a measurable tumor, whereas only one mouse</text>
<text top="553" left="57" width="240" height="9" font="font4" id="p1_t16" reading_order_no="21" segment_no="7" tag_type="text">in each group vaccinated with 10 6 IU VRP- neu or 10 5 IU</text>
<text top="565" left="57" width="241" height="9" font="font4" id="p1_t17" reading_order_no="22" segment_no="7" tag_type="text">VRP- neu had a measurable tumor (Fig. 2a,2b). These find-</text>
<text top="577" left="57" width="240" height="9" font="font4" id="p1_t18" reading_order_no="23" segment_no="7" tag_type="text">ings clearly demonstrate that vaccination three times with<i>neu </i></text>
<text top="588" left="57" width="240" height="10" font="font4" id="p1_t19" reading_order_no="24" segment_no="7" tag_type="text">either 10 5 IU or 10 6 IU VRP- neu protected mice from chal-</text>
<text top="600" left="57" width="241" height="9" font="font4" id="p1_t20" reading_order_no="25" segment_no="7" tag_type="text">lenge with A2L2 cells. VRP-HA failed to provide protection</text>
<text top="612" left="57" width="240" height="9" font="font4" id="p1_t21" reading_order_no="26" segment_no="7" tag_type="text">for any of the mice, and therefore the protective effect was</text>
<text top="624" left="57" width="240" height="9" font="font4" id="p1_t22" reading_order_no="27" segment_no="7" tag_type="text">specific for the vaccine containing the gene for HER2/ neu .</text>
<text top="647" left="57" width="236" height="8" font="font6" id="p1_t23" reading_order_no="28" segment_no="10" tag_type="title">Determination of the minimal effective vaccine dose in</text>
<text top="659" left="57" width="127" height="8" font="font6" id="p1_t24" reading_order_no="29" segment_no="10" tag_type="title">two tumor prevention models</text>
<text top="670" left="57" width="240" height="10" font="font4" id="p1_t25" reading_order_no="30" segment_no="11" tag_type="text">Because vaccination three times with 10 5 IU VRP- neu pre-</text>
<text top="683" left="57" width="240" height="9" font="font4" id="p1_t26" reading_order_no="31" segment_no="11" tag_type="text">vented tumor growth in a mammary fat pad, we next deter-</text>
<text top="694" left="57" width="241" height="9" font="font4" id="p1_t27" reading_order_no="32" segment_no="11" tag_type="text">mined the minimum number of VRP- neu particles and the</text>
<text top="706" left="57" width="241" height="9" font="font4" id="p1_t28" reading_order_no="33" segment_no="11" tag_type="text">minimum number of vaccinations necessary to significantly</text>
<text top="718" left="57" width="241" height="9" font="font4" id="p1_t29" reading_order_no="34" segment_no="11" tag_type="text">inhibit tumor growth. In the mammary fat pad prevention</text>
<text top="388" left="315" width="241" height="10" font="font4" id="p1_t30" reading_order_no="35" segment_no="4" tag_type="text">model, vaccination twice with 10 5 IU VRP- neu or vaccination</text>
<text top="400" left="315" width="241" height="10" font="font4" id="p1_t31" reading_order_no="36" segment_no="4" tag_type="text">three times with 10 4 IU VRP- neu completely prevented</text>
<text top="412" left="315" width="241" height="9" font="font4" id="p1_t32" reading_order_no="37" segment_no="4" tag_type="text">tumor growth in many mice and significantly reduced the</text>
<text top="424" left="315" width="241" height="9" font="font4" id="p1_t33" reading_order_no="38" segment_no="4" tag_type="text">tumor mass in the entire group compared with the tumor</text>
<text top="436" left="315" width="241" height="9" font="font4" id="p1_t34" reading_order_no="39" segment_no="4" tag_type="text">mass of the mice vaccinated three times with VRP-HA (Fig.<i>neu </i></text>
<text top="448" left="315" width="241" height="9" font="font4" id="p1_t35" reading_order_no="40" segment_no="4" tag_type="text">3a). Identical results were obtained in the experimental lung</text>
<text top="459" left="315" width="241" height="9" font="font4" id="p1_t36" reading_order_no="41" segment_no="4" tag_type="text">metastasis prevention model, in which mice were injected</text>
<text top="471" left="315" width="241" height="9" font="font4" id="p1_t37" reading_order_no="42" segment_no="4" tag_type="text">with A2L2 cells intravenously in the tail vein after vaccination</text>
<text top="483" left="315" width="241" height="9" font="font4" id="p1_t38" reading_order_no="43" segment_no="4" tag_type="text">(Fig. 3b). These results demonstrate that, in both tumor mod-</text>
<text top="494" left="315" width="241" height="10" font="font4" id="p1_t39" reading_order_no="44" segment_no="4" tag_type="text">els, vaccination three times with 10 4 IU VRP- neu or twice<i>neu </i></text>
<text top="506" left="315" width="241" height="9" font="font4" id="p1_t40" reading_order_no="45" segment_no="4" tag_type="text">with 10 5 IU VRP- neu significantly reduced the tumor mass<a href="">r (Fig. 2a,2b). These </a>find-</text>
<text top="518" left="315" width="241" height="9" font="font4" id="p1_t41" reading_order_no="46" segment_no="4" tag_type="text">and lung metastasis. In addition, several mice in each vacci-</text>
<text top="530" left="315" width="229" height="9" font="font4" id="p1_t42" reading_order_no="47" segment_no="4" tag_type="text">nated group were tumor free in mammary tissue or lungs.</text>
<text top="553" left="315" width="189" height="8" font="font6" id="p1_t43" reading_order_no="48" segment_no="8" tag_type="title">Vaccination of MMTV-c-neu transgenic mice</text>
<text top="565" left="315" width="241" height="9" font="font4" id="p1_t44" reading_order_no="49" segment_no="9" tag_type="text">MMTV-c- neu transgenic mice contain the activated rat neu</text>
<text top="577" left="315" width="241" height="9" font="font4" id="p1_t45" reading_order_no="50" segment_no="9" tag_type="text">gene under the control of the MMTV promoter and sponta-</text>
<text top="588" left="315" width="241" height="10" font="font4" id="p1_t46" reading_order_no="51" segment_no="9" tag_type="text">neously develop neu + breast tumors within 110â€“120 days</text>
<text top="600" left="315" width="241" height="9" font="font4" id="p1_t47" reading_order_no="52" segment_no="9" tag_type="text">[45]. Without intervention, all of the mice die of breast<i>neu </i></text>
<text top="612" left="315" width="241" height="9" font="font4" id="p1_t48" reading_order_no="53" segment_no="9" tag_type="text">cancer. We vaccinated groups of mice ( n = 10 per group)</text>
<text top="623" left="315" width="241" height="10" font="font4" id="p1_t49" reading_order_no="54" segment_no="9" tag_type="text">three times at 14-day intervals with 10 6 IU VRP- neu or 10 6</text>
<text top="636" left="315" width="241" height="9" font="font4" id="p1_t50" reading_order_no="55" segment_no="9" tag_type="text">IU VRP-HA and determined the effect on survival. Eight of</text>
<text top="647" left="315" width="240" height="9" font="font4" id="p1_t51" reading_order_no="56" segment_no="9" tag_type="text">the 10 mice vaccinated with VRP-HA were killed by 140</text>
<text top="659" left="315" width="240" height="9" font="font4" id="p1_t52" reading_order_no="57" segment_no="9" tag_type="text">days owing to moribundity, and the remaining two mice<i>neu</i></text>
<text top="671" left="315" width="241" height="9" font="font4" id="p1_t53" reading_order_no="58" segment_no="9" tag_type="text">were killed on day 195 (Fig. 4). None of the mice vacci-</text>
<text top="683" left="315" width="240" height="9" font="font4" id="p1_t54" reading_order_no="59" segment_no="9" tag_type="text">nated with VRP- neu showed any sign of illness at 240<b>Determination of the minimal effective vaccine dose in </b></text>
<text top="694" left="315" width="241" height="9" font="font4" id="p1_t55" reading_order_no="60" segment_no="9" tag_type="text">days, and breast tumors were not evident on palpation. The<b>two tumor prevention models</b></text>
<text top="706" left="315" width="241" height="9" font="font4" id="p1_t56" reading_order_no="61" segment_no="9" tag_type="text">mice in the VRP- neu -vaccinated group were killed at this</text>
<text top="718" left="315" width="241" height="9" font="font4" id="p1_t57" reading_order_no="62" segment_no="9" tag_type="text">time, and gross pathologic examination of the breasts fol-</text>
<text top="85" left="57" width="31" height="7" font="font0" id="p1_t58" reading_order_no="1" segment_no="1" tag_type="title">Figure 1</text>
<text top="343" left="57" width="483" height="7" font="font8" id="p1_t59" reading_order_no="4" segment_no="3" tag_type="text">Flow cytometric analysis of A2L2 cells with serum from mice vaccinated with virus-like replicon particles (VRP)- neu or VRP-hemagglutinin (HA)<i>neu </i></text>
<text top="343" left="448" width="96" height="7" font="font2" id="p1_t60" reading_order_no="5" segment_no="3" tag_type="text">or VRP-hemagglutinin (HA).</text>
<text top="352" left="57" width="494" height="7" font="font2" id="p1_t61" reading_order_no="6" segment_no="3" tag_type="text">Serum was collected 2 weeks after a single vaccination of Balb/c mice with 10 6 IU VRP- neu (filled curve) or 10 6 IU VRP-HA (open curve). The pri-</text>
<text top="362" left="57" width="488" height="7" font="font2" id="p1_t62" reading_order_no="7" segment_no="3" tag_type="text">mary serum was diluted with PBS (1:100), and FITC-labeled goat anti-mouse IgG diluted in PBS (1:1000) was used as the secondary antibody.</text>
<text top="297" left="272" width="99" height="22" font="font12" id="p1_t63" reading_order_no="3" segment_no="2" tag_type="figure">Fluorescence<i>neu </i></text>
<text top="210" left="84" width="0" height="22" font="font13" id="p1_t64" reading_order_no="2" segment_no="2" tag_type="figure">Counts</text>
</page>
</pdf2xml>
